Genetics of Lithium Response in Bipolar Disorder

Abstract

Introduction Lithium remains the best-established long-term treatment for bipolar disorder because of its efficacy in maintaining periods of remission and reducing the risk of suicide. Not all patients successfully respond to lithium treatment, and the individual response, including the occurrence of side effects, is highly variable and not easy to predict. The genetic basis of lithium response is supported by the fact that the response clusters in families. Likewise, recent high-throughput genomic analyses have shed light on its genetic architecture.

Methods This nonsystematic review summarizes the main results obtained in genetic association studies using lithium response as target trait.

Results These studies suggest that several genetic loci might modulate the way a patient responds to lithium maintenance treatment. Further studies to fully characterize the genetic architecture of lithium response are warranted.

Discussion The identification of genetic factors associated with lithium response will be important for (1) better understanding of lithium’s mode of action and (2) development of a predictive model for optimization of long-term treatment of bipolar disorder.

Key words

bipolar disorder treatment - genetics - bipolar disorder

• References

• 1 Yatham LN, Kennedy SH, Parikh SV. et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: Update 2013. Bipolar Disord 2013; 15: 1-44
• 2 Cipriani A, Barbui C, Salanti G. et al. Comparative efficacy and acceptability of antimanic drugs in acute mania: A multiple-treatments meta-analysis. Lancet Lond Engl 2011; 378: 1306-1315
• 3 Geddes JR, Calabrese JR, Goodwin GM. Lamotrigine for treatment of bipolar depression: Independent meta-analysis and meta-regression of individual patient data from five randomised trials. Br J Psychiatry J Ment Sci 2009; 194: 4-9
• 4 Geddes JR, Burgess S, Hawton K. et al. Long-term lithium therapy for bipolar disorder: Systematic review and meta-analysis of randomized controlled trials. Am J Psychiatry 2004; 161: 217-222
• 5 Hayes JF, Marston L, Walters K. et al. Lithium vs. valproate vs. olanzapine vs. quetiapine as maintenance monotherapy for bipolar disorder: A population-based UK cohort study using electronic health records. World Psychiatry 2016; 15: 53-58
• 6 Macritchie K, Geddes JR, Scott J. et al. Valproate for acute mood episodes in bipolar disorder. Cochrane Database Syst Rev 2003; 1: CD004052
• 7 Cipriani A, Reid K, Young AH. et al. Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder. Cochrane Database Syst Rev 2013; 10: CD003196
• 8 Goodwin GM, Bowden CL, Calabrese JR. et al A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. J Clin Psychiatry 2004; 65: 432-441
• 9 Goldsmith DR, Wagstaff AJ, Ibbotson T. et al. Spotlight on lamotrigine in bipolar disorder. CNS Drugs 2004; 18: 63-67
• 10 Smith LA, Cornelius V, Warnock A. et al. Effectiveness of mood stabilizers and antipsychotics in the maintenance phase of bipolar disorder: A systematic review of randomized controlled trials. Bipolar Disord 2007; 9: 394-412
• 11 Vasudev A, Macritchie K, Watson S. et al. Oxcarbazepine in the maintenance treatment of bipolar disorder. Cochrane Database Syst Rev 2008; 1: CD005171
• 12 Gitlin M, Frye MA. Maintenance therapies in bipolar disorders. Bipolar Disord 2012; 14 (Suppl. 02) 51-65
• 13 Baldessarini RJ, Tondo L, Baethge CJ. et al. Effects of treatment latency on response to maintenance treatment in manic-depressive disorders. Bipolar Disord 2007; 9: 386-393
• 14 Berghöfer A, Alda M, Adli M. et al. Long-term effectiveness of lithium in bipolar disorder: A multicenter investigation of patients with typical and atypical features. J Clin Psychiatry 2008; 69: 1860-1868
• 15 Drancourt N, Etain B, Lajnef M. et al. Duration of untreated bipolar disorder: Missed opportunities on the long road to optimal treatment. Acta Psychiatr Scand 2013; 127: 136-144
• 16 Solomon DA, Keitner GI, Miller IW. et al. Course of illness and maintenance treatments for patients with bipolar disorder. J Clin Psychiatry 1995; 56: 5-13
• 17 MacQueen GM, Young LT, Robb JC. et al. Effect of number of episodes on wellbeing and functioning of patients with bipolar disorder. Acta Psychiatr Scand 2000; 101: 374-381
• 18 Kessing LV, Hellmund G, Andersen PK. Predictors of excellent response to lithium: Results from a nationwide register-based study. Int Clin Psychopharmacol 2011; 26: 323-328
• 19 Kessing LV, Vradi E, Andersen PK. Starting lithium prophylaxis early v. late in bipolar disorder. Br J Psychiatry J Ment Sci 2014; 205: 214-220
• 20 Joyce K, Thompson A, Marwaha S. Is treatment for bipolar disorder more effective earlier in illness course? A comprehensive literature review. Int J. Bipolar Disord 2016; 4: 19
• 21 Ibi D, de la Fuente Revenga M, Kezunovic N. et al. Antipsychotic-induced Hdac2 transcription via NF-κB leads to synaptic and cognitive side effects. Nat Neurosci 2017; 20: 1247-1259
• 22 Post RM, Altshuler LL, Frye MA. et al. Complexity of pharmacologic treatment required for sustained improvement in outpatients with bipolar disorder. J Clin Psychiatry 2010; 71: 1176-1186
• 23 Peselow ED, Clevenger S, IsHak WW. Prophylactic efficacy of lithium, valproic acid, and carbamazepine in the maintenance phase of bipolar disorder: A naturalistic study. Int Clin Psychopharmacol 2016; 31: 218-223
• 24 Garnham J, Munro A, Slaney C. et al. Prophylactic treatment response in bipolar disorder: Results of a naturalistic observation study. J Affect Disord 2007; 104: 185-190
• 25 Baldessarini RJ, Tondo L. Does lithium treatment still work? Evidence of stable responses over three decades. Arch Gen Psychiatry 2000; 57: 187-190
• 26 Rybakowski JK, Chlopocka-Wozniak M, Suwalska A. The prophylactic effect of long-term lithium administration in bipolar patients entering treatment in the 1970 s and 1980 s. Bipolar Disord 2001; 3: 63-67
• 27 Miura T, Noma H, Furukawa TA. et al. Comparative efficacy and tolerability of pharmacological treatments in the maintenance treatment of bipolar disorder: A systematic review and network meta-analysis. Lancet Psychiatry 2014; 1: 351-359
• 28 Cipriani A, Hawton K, Stockton S. et al. Lithium in the prevention of suicide in mood disorders: Updated systematic review and meta-analysis. BMJ 2013; 346: f3646
• 29 Tondo L, Hennen J, Baldessarini RJ. Lower suicide risk with long-term lithium treatment in major affective illness: A meta-analysis. Acta Psychiatr Scand 2001; 104: 163-172
• 30 Hayes JF, Pitman A, Marston L. et al. Self-harm, unintentional injury, and suicide in bipolar disorder during maintenance mood stabilizer treatment: A UK population-based electronic health records study. JAMA Psychiatry 2016; 73: 630-637
• 31 Song J, Sjölander A, Joas E. et al. Suicidal behavior during lithium and valproate treatment: A within-individual 8-year prospective study of 50,000 patients with bipolar disorder. Am J Psychiatry 2017; 174: 795-802
• 32 Müller-Oerlinghausen B, Berghöfer A, Bauer M. Bipolar disorder. Lancet Lond Engl 2002; 359: 241-247
• 33 Gitlin M. Lithium side effects and toxicity: Prevalence and management strategies. Int J. Bipolar Disord 2016; 4: 27
• 34 Malhi GS, Gessler D, Outhred T. The use of lithium for the treatment of bipolar disorder: Recommendations from clinical practice guidelines. J Affect Disord 2017; 217: 266-280
• 35 Kleindienst N, Engel R, Greil W. Which clinical factors predict response to prophylactic lithium? A systematic review for bipolar disorders. Bipolar Disord 2005; 7: 404-417
• 36 Grof P, Duffy A, Cavazzoni P. et al. Is response to prophylactic lithium a familial trait?. J Clin Psychiatry 2002; 63: 942-947
• 37 Sportiche S, Geoffroy PA, Brichant-Petitjean C. et al. Clinical factors associated with lithium response in bipolar disorders. Aust N Z J Psychiatry 2017; 51: 524-530
• 38 Manchia M, Adli M, Akula N. et al. Assessment of response to lithium maintenance treatment in bipolar disorder: A Consortium on Lithium Genetics (ConLiGen) report. PloS One 2013; 8: e65636
• 39 Tondo L, Baldessarini RJ, Floris G. Long-term clinical effectiveness of lithium maintenance treatment in types I and II bipolar disorders. Br J Psychiatry Suppl 2001; 41: s184-s190
• 40 Mertens J, Wang QW, Kim Y. et al. Differential responses to lithium in hyperexcitable neurons from patients with bipolar disorder. Nature 2015; 527: 95-99
• 41 Stern S, Santos R, Marchetto MC. et al. Neurons derived from patients with bipolar disorder divide into intrinsically different sub-populations of neurons, predicting the patients’ responsiveness to lithium. Mol Psychiatry 2018; 23: 1453-1465
• 42 Grof P. Sixty years of lithium responders. Neuropsychobiology 2010; 62: 8-16
• 43 Grof P, Alda M, Grof E. et al. The challenge of predicting response to stabilising lithium treatment. The importance of patient selection. Br J Psychiatry Suppl 1993; 16-19
• 44 Calabrese JR, Fatemi SH, Kujawa M. et al. Predictors of response to mood stabilizers. J Clin Psychopharmacol 1996; 16: 24S-31S
• 45 Maj M. Clinical prediction of response to lithium prophylaxis in bipolar patients: A critical update. Lithium 1992; 3: 15-21
• 46 McCarthy MJ, Leckband SG, Kelsoe JR. Pharmacogenetics of lithium response in bipolar disorder. Pharmacogenomics 2010; 11: 1439-1465
• 47 Rohayem J, Baylé JF, Richa S. [Predictors of prophylactic response to lithium]. L’Encéphale 2008; 34: 394-399
• 48 Maj M, Pirozzi R, Starace F. Previous pattern of course of the illness as a predictor of response to lithium prophylaxis in bipolar patients. J Affect Disord 1989; 17: 237-241
• 49 Passmore MJ, Garnham J, Duffy A. et al. Phenotypic spectra of bipolar disorder in responders to lithium versus lamotrigine. Bipolar Disord 2003; 5: 110-114
• 50 Koukopoulos A, Reginaldi D, Tondo L. et al. Course sequences in bipolar disorder: Depressions preceding or following manias or hypomanias. J Affect Disord 2013; 151: 105-110
• 51 Kleindienst N, Engel RR, Greil W. Psychosocial and demographic factors associated with response to prophylactic lithium: A systematic review for bipolar disorders. Psychol Med 2005; 35: 1685-1694
• 52 Ikeda A, Kato T. Biological predictors of lithium response in bipolar disorder. Psychiatry Clin Neurosci 2003; 57: 243-250
• 53 Greil W, Kleindienst N, Erazo N. et al. Differential response to lithium and carbamazepine in the prophylaxis of bipolar disorder. J Clin Psychopharmacol 1998; 18: 455-460
• 54 Kleindienst N, Greil W. Differential efficacy of lithium and carbamazepine in the prophylaxis of bipolar disorder: Results of the MAP study. Neuropsychobiology 2000; 42 (Suppl. 01) 2-10
• 55 Duffy A, Alda M, Milin R. et al. A consecutive series of treated affected offspring of parents with bipolar disorder: Is response associated with the clinical profile?. Can J Psychiatry 2007; 52: 369-376
• 56 Alda M, Grof P, Rouleau GA. et al. Investigating responders to lithium prophylaxis as a strategy for mapping susceptibility genes for bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29: 1038-1045
• 57 Song J, Bergen SE, Di Florio A. et al. Genome-wide association study identifies SESTD1 as a novel risk gene for lithium-responsive bipolar disorder. Mol Psychiatry 2016; 21: 1290-1297
• 58 Severino G, Squassina A, Costa M. et al. Pharmacogenomics of bipolar disorder. Pharmacogenomics 2013; 14: 655-674
• 59 Budde M, Degner D, Brockmöller J. et al. Pharmacogenomic aspects of bipolar disorder: An update. Eur Neuropsychopharmacol 2017; 27: 599-609
• 60 Alda M. Lithium in the treatment of bipolar disorder: Pharmacology and pharmacogenetics. Mol Psychiatry 2015; 20: 661-670
• 61 Geoffroy PA, Bellivier F, Leboyer M. et al. Can the response to mood stabilizers be predicted in bipolar disorder?. Front Biosci Elite Ed 2014; 6: 120-138
• 62 Pisanu C, Melis C, Squassina A. Lithium pharmacogenetics: Where do we stand?. Drug Dev Res 2016; 77: 368-373
• 63 Lopez de Lara C, Jaitovich-Groisman I, Cruceanu C. et al. Implication of synapse-related genes in bipolar disorder by linkage and gene expression analyses. Int J Neuropsychopharmacol 2010; 13: 1397-1410
• 64 Morissette J, Villeneuve A, Bordeleau L. et al. Genome-wide search for linkage of bipolar affective disorders in a very large pedigree derived from a homogeneous population in Quebec points to a locus of major effect on chromosome 12q23-q24. Am J Med Genet 1999; 88: 567-587
• 65 Ewald H, Wang AG, Vang M. et al. A haplotype-based study of lithium responding patients with bipolar affective disorder on the Faroe Islands. Psychiatr Genet 1999; 9: 23-34
• 66 Maier RM, Visscher PM, Robinson MR. et al. Embracing polygenicity: A review of methods and tools for psychiatric genetics research. Psychol Med 2017; 1-19
• 67 Rybakowski JK, Abramowicz M, Szczepankiewicz A. et al. The association of glycogen synthase kinase-3beta (GSK-3β) gene polymorphism with kidney function in long-term lithium-treated bipolar patients. Int J. Bipolar Disord 2013; 1: 8
• 68 Gratten J, Wray NR, Keller MC. et al. Large-scale genomics unveils the genetic architecture of psychiatric disorders. Nat Neurosci 2014; 17: 782-790
• 69 Schulze TG, Alda M, Adli M. et al. The International Consortium on Lithium Genetics (ConLiGen): An initiative by the NIMH and IGSLI to study the genetic basis of response to lithium treatment. Neuropsychobiology 2010; 62: 72-78
• 70 Hou L, Heilbronner U, Degenhardt F. et al. Genetic variants associated with response to lithium treatment in bipolar disorder: A genome-wide association study. Lancet Lond Engl 2016; 387: 1085-1093
• 71 Hunsberger JG, Chibane FL, Elkahloun AG. et al. Novel integrative genomic tool for interrogating lithium response in bipolar disorder. Transl Psychiatry 2015; 5: e504
• 72 Perlis RH, Smoller JW, Ferreira MAR. et al. A genomewide association study of response to lithium for prevention of recurrence in bipolar disorder. Am J Psychiatry 2009; 166: 718-725
• 73 Squassina A, Manchia M, Borg J. et al. Evidence for association of an ACCN1 gene variant with response to lithium treatment in sardinian patients with bipolar disorder. Pharmacogenomics 2011; 12: 1559-1569
• 74 Chen CH, Lee CS, Lee MTM. et al. Variant GADL1 and response to lithium therapy in bipolar I disorder. N Engl J Med 2014; 370: 119-128
• 75 Consortium on Lithium Genetics. Hou L, Heilbronner U. et al. Variant GADL1 and response to lithium in bipolar I disorder. N Engl J Med 2014; 370: 1857-1859
• 76 Oedegaard KJ, Alda M, Anand A. et al. The Pharmacogenomics of Bipolar Disorder study (PGBD): Identification of genes for lithium response in a prospective sample. BMC Psychiatry 2016; 16: 129
• 77 Tobe BTD, Crain AM, Winquist AM. et al. Probing the lithium-response pathway in hiPSCs implicates the phosphoregulatory set-point for a cytoskeletal modulator in bipolar pathogenesis. Proc Natl Acad Sci USA 2017; 114: E4462-E4471
• 78 Middeldorp CM, Wray NR. The value of polygenic analyses in psychiatry. World Psychiatry 2018; 17: 26-28